October 18, 2007 – XTENT Inc. announced that two-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company’s investigational Custom NX drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation’s (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.
In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.
Schedule of Events
Sunday, October 21
Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting Modular Stent Program (Focus on Multivessel and Diffuse Disease)
Pieter Stella, M.D., director of Cardiology, University Medical Center, Utrecht, Netherlands, will present an historical overview and current perspective on the treatment of multivessel coronary disease and the treatment of long lesions. An overview of the Custom NX DES System with respect to the treatment of multivessel and diffuse disease will be discussed, along with the one-year follow-up results of the CUSTOM II Trial.
Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington Convention Center
Event: Evening Symposium – Delivering Safety to Today’s Patients
Professor Eberhard Grube, M.D., chief of Cardiology at the HELIOS Heart Center in Siebgurg, Germany and principal investigator of the CUSTOM I and II clinical trials, will review the results to date from Biolimus A9 DES clinical trials and registries. Professor Grube will present two-year results from the CUSTOM I clinical trial and one-year results from the CUSTOM II clinical trial.
Bernard de Bruyne, M.D., Ph.D, Cardiovascular Center, OLV Hospital in Aalst, Belgium, will provide an overview of the Custom NX technology in a presentation titled "XTENT Custom NX DES Systems: A Novel Approach to the Percutaneous Treatment of Coronary Artery Disease (CAD)."
Time/Location: 8:00-10:00 p.m. EDT; Renaissance Washington, D.C. Hotel, Grand Ballroom, 999 Ninth Street NW
Monday, October 22
Event: Analyst Webcast and Teleconference on CUSTOM I and CUSTOM II Data
For more information: www.xtentinc.com
July 02, 2024 
